Optimal dose of intrathecal hyperbaric bupivacaine with opioids for cesarean delivery:a prospective, randomized, double-blinded, dose-ranging study

Optimal dose of intrathecal hyperbaric bupivacaine with opioids for cesarean delivery:a prospective, randomized, double-blinded, dose-ranging study - Optimal dose of intrathecal hyperbaric bupivacaine with opioids for cesarean delivery

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000023692

Enrollment

Registered

2016-08-22

Start date

2010-05-26

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cesarean delivery

Interventions

intrathecal 6mg hyperbaric bupivacaine co-administered with fentanyl 15 mcg and morphine 75 mcg intrathecal 7mg hyperbaric bupivacaine co-administered with fentanyl 15 mcg and morphine 75 mcg intrathe

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: 1. American Society Anesthesiologists physical status class I, or II 2. height between 140 and 180 cm 3. singleton pregnancy 4. gestational age of more 37 completed weeks

Exclusion criteria

Exclusion criteria: 1. active labor 2. ruptured membranes 3. three or more previous Cesarean deliveries 4. gestational diabetes 5. pregnancy induced hypertension 6. intrauterine growth retardation 7. placenta previa 8. body mass index more than 35

Design outcomes

Primary

Measure	Time frame
the optimal dose of hyperbaric bupivacaine co-administered with fentanyl and morphine for Cesarean delivery without supplemental analgesia	—

Secondary

Measure	Time frame
1. the cumulative dose of phenylephrine 2. frequency of adverse events 3. maternal satisfaction	—

Countries

Japan

Contacts

Public ContactEiko Onishi

Took University Hospital Department of anesthesiology

e-onishi@med.tohoku.ac.jp+08-22-717-7321

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026